SCHEMBL2118235

SCHEMBL2118235

Cc1cc(-c2ccc(C)c(NS(=O)(=O)c3ccn(C)c3)c2)cs1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.41
▸ GHSR Q92847 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ TP53 P04637 2/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ MCOLN3 Q8TDD5 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ DRD2 P14416 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ HTR6 P50406 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2117692 0.85 MAPT (0.41) MAPTGHSRSMN1; SMN2TP53KMT2A
SCHEMBL2119347 0.84 KMT2A (0.50) MAPTGHSRSMN1; SMN2TP53KMT2A
SCHEMBL2117319 0.79 ACLY (0.50) MAPTDRD2HTR2AHTR2CDRD3
SCHEMBL2117662 0.78 POLB (0.42) MAPTGHSRTP53KMT2AMEN1
SCHEMBL3792512 0.76 TRIM24 (0.57) MAPTGHSRSMN1; SMN2TP53ALDH1A1
SCHEMBL2120461 0.76 CYP2C9 (0.50) MAPTSMN1; SMN2TP53KMT2AMEN1
SCHEMBL2119311 0.76 ALDH1A1 (0.46) MAPTGHSRSMN1; SMN2TP53KMT2A
SCHEMBL2117167 0.76 CYP2D6 (0.42) MAPTGHSRSMN1; SMN2KMT2AMEN1
SCHEMBL2119240 0.76 GHSR (0.42) MAPTGHSRSMN1; SMN2KMT2AMEN1
SCHEMBL2117617 0.75 CYP3A4 (0.46) MAPTGHSRSMN1; SMN2TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 — — US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MAPT 4747/4885GHSR 1390/4885SMN1; SMN2 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback